Six Healthcare Stocks With Nice Upside Potential
Finbox io | Feb 12, 2017 02:32PM ET
This earnings season continues to be a story of growth. According to Zack’s Investment Research , 319 members of the S&P 500 have reported as of Wednesday, February 8th. Total earnings from these companies have grown 5.8% in Q4 compared to 2.8% in Q3 while revenues have increased 2.8% in Q4 vs 2.0% in Q3. Overall, S&P 500 member earnings remain on pace to reach their highest level in nearly two years.
One standout sector has been medical/healthcare stocks. So far these companies have reported revenue growth of 5.9% with 57% beating their estimates. Immediately following the earnings release, these healthcare companies have enjoyed a positive 1.4% stock price impact.
So let’s take a look at some fundamentally attractive healthcare stocks that could jump on earnings this week?6 Healthcare
h3 Stocks That Could Jump On Earnings/h3According to finance , there are 65 companies listed in the healthcare sector expected to report earnings this week (2/13–2/17). However, only six appear to be trading below their finbox.io fair value estimate: Charles River Laboratories (NYSE:CRL), Alkermes (NASDAQ:ALKS), Laboratory Corporation of America (NYSE:LH), Icon PLC (NASDAQ:ICLR), Express Scripts (NASDAQ:ESRX) and Alexion Pharmaceuticals Inc (NASDAQ:ALXN).
Charles River Laboratories is an early-stage contract research company providing drug discovery and preclinical development services worldwide. The company is expected to report earnings on Tuesday while eight valuation models conclude a fair value range of $86.11 to $118.98 and $104.37 at the midpoint.
Alkermes is a biopharmaceutical company that develops pharmaceutical products designed to address unmet medical needs. The company is expected to report on Wednesday and seven separate valuation analyses imply a fair value of $68.14, slightly above Wall Street’s target.
Laboratory Corporation of America operates as an independent clinical lab. Ten cash flow valuation models imply that shares are approximately 20% undervalued. The company is expected to report earnings on Thursday before the market opens.
Get The News You Want
ICON is a contract research organization that provides outsourced development services to the pharmaceutical and medical device industries. The research firm is scheduled to report earnings on Thursday and the stock is currently trading near its 52-week high. However, finbox.io fair value data implies that shares are still 18% undervalued.
Express Scripts operates as a pharmacy benefit management company. Seven cash flow analyses imply that the company is approximately 12% undervalued prior to reporting earnings (expected Tuesday). This compares to Wall Street’s price target of $81.11 which implies over 20% upside.
Alexion is a biopharmaceutical company that develops and commercializes life-transforming therapeutic products. The company is scheduled to report earnings on Thursday. The Wall Street consensus price target of $167.93 is above finbox.io’s fair value estimate of $133.34. Both estimates imply positive margin of safety.
These healthcare stocks all have strong fundamentals and could easily trade higher following their earnings reports this week. Value investors may want to take a closer look.
/h3
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.